Ignite Creation Date:
2025-12-24 @ 11:35 PM
Ignite Modification Date:
2025-12-30 @ 12:08 AM
Study NCT ID:
NCT01340456
Status:
COMPLETED
Last Update Posted:
2011-07-11
First Post:
2011-04-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cholesterol Metabolites as Markers for CYP3A Induction
Sponsor:
Karolinska University Hospital
Organization:
Study Overview
Official Title:
Induction of Drug Metabolism by Rifampicin to Compare the Endogenous Biomarker 4beta-OHcholesterol With the Probe Drug Midazolam as Quantitative Markers for Cytochrome P450 3A4 Induction
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this study are:
* To investigate if the endogenous cholesterol metabolite, 4beta-OHcholesterol could be used as a marker for induction of cytochrome P450 (CYP) 3A4.
* To compare 4beta-OHcholesterol with midazolam as a marker for induction of CYP3A4.
* To investigate if the endogenous cholesterol metabolite, 4beta-OHcholesterol could be used as a marker for induction of cytochrome P450 (CYP) 3A4.
* To compare 4beta-OHcholesterol with midazolam as a marker for induction of CYP3A4.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: